Home
>
US Stocks
>
Stoke Therapeutics Inc
Stoke Therapeutics Inc
STOK

Stoke Therapeutics Inc (STOK)

$23.2310.17%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
23.87
Today Low/High
22.91 / 23.87
52 Week Low/High
$24.22 / $71.58
Market Cap
$956.21M

Company Details

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company's belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
Organisation
Stoke Therapeutics Inc
Headquaters
Bedford, Massachusetts, US
Employees
79
Industry
Health Technology
CEO
Edward Kaye

Discover more

Frequently Asked Questions

What is Stoke Therapeutics Inc (STOK) share price today?

Can Indians buy Stoke Therapeutics Inc (STOK) shares?

How can I buy Stoke Therapeutics Inc (STOK) shares from India?

Can Fractional shares of Stoke Therapeutics Inc (STOK) be purchased?

What are the documents required to start investing in Stoke Therapeutics Inc (STOK) stocks?

We are a SEBI registered investement advisor